Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - ImmunoCellular Therapeutics, Ltd. | Financial_Report.xls |
| 10-Q - 10-Q - ImmunoCellular Therapeutics, Ltd. | imuc-10q_20150331.htm |
| EX-32.2 - EX-32.2 - ImmunoCellular Therapeutics, Ltd. | imuc-ex322_201503319.htm |
| EX-31.1 - EX-31.1 - ImmunoCellular Therapeutics, Ltd. | imuc-ex311_201503316.htm |
| EX-31.2 - EX-31.2 - ImmunoCellular Therapeutics, Ltd. | imuc-ex312_201503318.htm |
| EX-4.1 - EX-4.1 - ImmunoCellular Therapeutics, Ltd. | imuc-ex41_20150331103.htm |
| EX-10.1 - EX-10.1 - ImmunoCellular Therapeutics, Ltd. | imuc-ex101_20150331104.htm |
| EX-10.2 - EX-10.2 - ImmunoCellular Therapeutics, Ltd. | imuc-ex102_20150331201.htm |
Exhibit 32.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
Pursuant to the requirement set forth in Rule 13a -14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:
|
1. |
The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2015 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and |
|
2. |
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: May 11, 2015 |
By: |
/s/ Andrew Gengos |
|
|
|
|
Name: |
Andrew Gengos |
|
|
|
Title: |
President and Chief Executive Officer |